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Treatment of Cloudman S91 melanoma cells with retinoic acid (RA) inhibits MSH-induced tyrosinase activity and melanin formation [(1990) J. In- 
vest. Dermatol. 94, 4614641. We report here, however, that in spite of inhibiting MSH-induced pigmentation, RA treatment caused a marked 
increase in MSH binding capacity for both cell surface and internal MSH binding sites. The stimulation was dose- and time-dependent and 
reversible, with half-maximal effects seen at 2 PM RA. Stimulation of MSH binding was seen as early as 3 h after exposure of cells to RA. Cell 
surface and internal binding activity increased in concert. Scatchard analyses indicated that increased MSH binding resulted from a 34-fold increase 
in the number of sites with no significant difference in their affinity for MSH. It appears that in suppressing MSH-induced melanogenesis, RA 
elicited a compensatory up-regulation of the MSH receptor system. 
Melanoma; Melanotropin receptor; Retinoic acid 
1. INTRODUCTION 
Retinoic acid (RA) has a wide ringe of biological ef- 
fects on normal and transformed cells in culture and in 
vivo. In particular, teratocarcinoma, neuroblastoma 
and melanoma cell lines stop proliferation and in some 
cases exhibit altered phenotypic expression in response 
to RA treatment (for review see [l]). Melanin synthesis 
has been used as an indicator of melanoma cell differen- 
tiation, and there have been several reports showing 
that retinoic acid can act as either a stimulator or sup- 
pressor of basal melanization in cultured melanoma 
cells [2-51. We studied the effects of retinoic acid on in- 
ducible melanization, either hormonally with 
melanocyte stimulating hormone (MSH), or phar- 
macologically with cholera toxin, isobutylmethylxan- 
thine (IBMX), and found that in all cases retinoic acid 
is a potent inhibitor of the induction process [6]. This 
was true not only for retinoic acid, but for a number 
structurally unrelated compounds which are known in 
other systems to induce differentiation (dimethylsulfox- 
ide, hexamethylene bisacetamide, sodium butyrate). 
We were surprised to find, however, that even though 
these agents each inhibited melanocyte-stimulating 
hormone-induced melanogenesis, they did not inhibit 
MSH binding capacity of the melanoma cells, and in 
fact markedly stimulated MSH binding [7]. It appeared 
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that in suppressing induced melanogenesis, the agents 
elicited a compensatory up-regulation of the MSH 
receptor system. This report details the nature of the in- 
creased binding capacity of Cloudman melanoma cells 
for MSH following exposure to retinoic acid. 
2. MATERIALS AND METHODS 
2.1 Cell line and culture conditions 
The Cloudman S91 murine melanoma cell line ‘PSI-HGPRT-1’ 
was used in all studies [8]. Cells were cultured in Corning tissue 
culture flasks at 37”C, 90% humidity and 5% CO2 in Ham’s FlO 
medium supplemented with horse serum (10%) penicillin (100 
IU/ml) and streptomycin (100 mg/ml). Cells were passaged twice 
weekly after removal from the substratum with Joklik’s medium con- 
taining 1 mM EDTA. 
2.2 Treatment of cells with retinoic acid 
Retinoic acid was obtained from Sigma Chemicals (St. Louis, MO), 
dissolved at 10 mM in DMSO, and stored at -20°C kept in foil- 
wrapped containers protected from light. Cells were plated for 12-24 
h in plain culture medium prior to any experimental dditions. At the 
end of treatment, cells were removed from substratum by incubation 
with Joklik’s buffered saline containing EDTA (1 mM), counted with 
a Coulter counter and pelleted by centrifugation. 
2.3 Binding of ‘z51-fl-MSH to intact cells 
Iodination of P-MSH and isolation of the mono-iodinated peptide 
(retaining full biological activity as assayed by its ability to stimulate 
tyrosinase) by reverse phase liquid chromatography were carried out 
in this laboratory by a modification [9] of the method of Lambert and 
Lerner [lo]. The binding of ‘X -I-P-MSH to cells was assayed as 
previously described [1 I]. Non-specific binding ranged from 5 to 10% 
of the total binding, and was subtracted to generate the displayed 
values. 
2.4 Internal binding sites for ‘251-&M7H 
Cells were removed from flasks, chilled to 4”C, pelleted by cen- 
trifugation (700 x g, 10 min), resuspended in hypotonic buffer (10 
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mM ‘Iris-HCl, 1 mM CaC12, 1 mM MgCL2, pH 7.8) at 4”C, and lysed 
by passages through needles as previously described [I I]. The lysate 
was then centrifuged at 156000 x g for 20 min. The pellet fraction 
was then resus~nded in MSH binding buffer (140 mM NaCl, 5 mM 
KCl, 10 mM NaaHP04, 1 mM KHzPOG, 0.1% glucose) incubated 
with ‘2’I-&MSH (1 nM) in the presence or absence of a 5000-fold ex- 
cess of non-radioactive /3-MSH in a shaking water bath (lO°C) for 
90-120 min, layered onto a stepwise sucrose gradient (8-80%), and 
centrifuged at 156000 x g for 60 min. Fractions were collected and 
refractive indices determined as described [1 I]. 
2.5 Statrjtical analysis 
Statistical analyses of the data were done using the STATVIEW 
program (Abacus). P values were calculated from one-tail paired t- 
test using the same program. 
3. RESULTS 
3.1 Dose-response 
The relationship between MSH binding and the con- 
centration of RA administered was determined in 
Cloudman S91 melanoma cells pretreated with various 
concentrations of RA for 20 h (Fig. 1). The MSH bind- 
ing was stimulated by RA, with a significant (P < 0.05) 
increase (160 f 16% of control) detected at RA concen- 
trations greater than low6 M. Maximal stimulation, 
(223 st 23% of control, P < 0.05) was observed at 
4 x 10-6MRA. 
3.2 Time course and re~ersibiiity 
Stimulation of MSH binding by RA as a function of 
time was determined. Fig. 2 shows hormone binding by 
cells exposed to 4 x 10m6 M RA up to 42 h. A signifi- 
cant increase in MSH binding was detected in treated 
ceils after 3 h (116 + 8% of control, P ~0.01). Max- 
imal binding was observed after 18-24 h (195 + 29% of 
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Fig. 1. Dose-dependent s imulation of MSH receptor activity by RA. 
Cloudman S91 mouse melanoma cells were incubated with indicated 
doses of RA for 20 h. Specific counts bound were determined as 
described in section 2. Results are expressed as percentage of the 
control specific binding. Each point represents mean i SD of three 
determinations from a representative experiment. The experiment was 
repeated twice with similar resufts. 
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Fig. 2. Time-dependent effect of RA on MSH receptor activity and its 
reversibility. Cloudman S91 mouse melanoma cells were incubated 
with 4 &M RA for the indicated time periods, after which the cells 
were taken up by Joklik’s buffered saiine containing 1 mM EDTA for 
MSH receptor binding assay as described in section 2. The arrow 
indicates the point of retinoic acid withdrawal. Values represent he 
mean f SD of 3 separate xperiments done in triplicate. 
The increased binding detected in cells treated with 4 x 
lo- 6 M RA for 6 h returned to normal within 24 h after 
removal of drug. 36-48 h after removal of RA, MSH 
binding activity consistently rose to levels even higher 
than those obtained by initial treatment with the drug. 
3.3 3~ndi~g competit~un and ~catc~ard una~ys~s 
To further characterize the effect of RA treatment on 
MSH binding, the cells were preincubated for 20 h with 
either RA (4 x 10m6 M) or DMSO (0.02010) as control, 
and the binding of 1251-&MSH was measured in the 
presence of various concentrations of unlabelled hor- 
mone (Fig. 3). In untreated cells, the h~f-rn~irn~ in- 
hibition of binding was achieved by the inclusion of 7 
nM unlabelled hormone, whereas in RA-treated cells 30 
nM unlabeled hormone was required to effect the same 
inhibition. 
Scatchard analyses of the binding data showed a cur- 
vilinear plot which could be explained either by a two- 
site model or by negative cooperativity. Using a two-site 
model and computerized linear regression analysis, we 
found that untreated cells expressed an average of 6317 
k 2025 (mean r+- SD) high affinity MSH binding sites 
per cell, whereas RA-treated cells expressed 28200 f 
6700 high affinity sites per cell (Fig. 3, inset). The 
number of ‘low affinity’ sites was 65900 f 8600 for 
control cells and 263 900 ric 75 800 for RA-treated cells. 
Differences in equilibrium dissociation constants be- 
tween control and RA-treated cells were insignificant, 
approximate & values being 1 nM and 15 nM for high 
and low affinity sites, respectively, suggesting that the 
mechanism by which RA increased MSH binding 
capacity involved increasing the number of MSH recep- 
tors. 
3.4 rnterna~ binding sites 
We have previously described the presence of internal 
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Fig. 3. Competition-inhibition curves of tz51$3-MSH binding with unlabelled &MSH in Cloudman S91 cells treated (0) or untreated (0) with RA 
(4 PM) for 20 h. Cells (2.5 x 105) were incubated in the presence of 1 nM ‘Z51-&MSH plus the indicated concentrations (abscissa) of unlabelled 
@MSH. The Values are the mean f SD of three determinations at each concentration of unlabelled P-MSH. The experiments were repeated twice 
with similar results. Scatchard analyses of the data are shown in the inset. 
binding sites for MSH in Cloudman melanoma cells, (245 + 22% control, P c 0.01) which paralleled that of 
and demonstrated that these sites correlated with the surface receptors was noted (Fig. 4). Because of the 
cellular responsiveness to the hormone [l 11. We technical difficulties involved in the manipulation of 
therefore determined whether such sites were also af- these fractions, Scatchard analysis could not be per- 
fected by RA treatment of the cells. When the dense formed to determine whether this increase was a func- 
particulate fraction from treated cells was analyzed for tion of altered receptor affinity, receptor number, or 
the presence of MSH binding activity, a large increase both. 
Internal 
Fig. 4. Effect of RA on internal MSH binding sites from Cloudman 
S91 cells. Cells were treated with rZ or without RA 0 (4 PM) for 36 
h. After treatment, cell surface MSH binding sites and internal MSH 
binding sites were assayed. Results are expressed as percentage of con- 
trol specific binding. The experiment was repeated three times with 
similar results. Data points represent he mean +_ SD of triplicate 
determinations from a representative xperiment. Asterisks indicate 
values significantly different from control at *P < 0.001 and 
**p < 0.01. 
4. DISCUSSION 
Retinoic acid increased the binding of MSH to its cell 
surface receptor in a time- and dose-dependent manner. 
The optimum concentration and time were found to be 
4 PM and 24 h, respectively. The effects were reversible 
within 24 h after removal of the drug. Scatchard 
analysis of the competitive inhibition of 12SI-fl-MSH 
binding by non-radioactive hormone indicated that RA 
treatment increased the receptor number of both the 
high and low affinity sites per cell by 3-4-fold. The 
receptor number for untreated cells (approximately 
6000) was similar to the numbers reported by others for 
Cloudman melanoma cells [ 10,121. 
The biochemical basis for receptor up-regulation by 
RA could be due to an increased rate of synthesis, a 
decreased rate of receptor degradation, a blocking of 
internalization, or a stimulation of externalization of 
receptor. Two pieces of evidence mitigate against a role 
for alterations in receptor internalization or externaliza- 
tion as the cause of cell surface up-regulation. First, 
207 
Volume 276, number 1,2 FEBSLETTERS December 1990 
both internal and surface receptor activity were increas- 
ed by RA in concert. Second, although retinoic acid 
blocks the effects of MSH on melanogenesis, it do(ts not 
interfere with MSH-induced changes in cellular mor- 
phology and growth, suggesting that at least the initial 
steps in the signal transduction pathway are not disturb- 
ed by RA [6,7]. 
The regulation of MSH receptor levels has important 
biologic implications. MSH causes an increase in 
cellular levels of CAMP [ 131, stimulation of tyrosinase 
activity and melanin content [14], as well as changes in 
growth and morphology of Cloudman S91 melanoma 
cells [15]. Yet, despite its stimulatory effects on MSH 
binding, RA inhibits MSH-induced tyrosinase activity 
and melanin production [6], but not MSH-induced 
changes in the rate of cell proliferation or morphology 
[7]. Therefore, RA causes only a partial modulation of 
the cellular responses to MSH suggesting that the ef- 
fects of MSH on pigmentation, growth, and mor- 
phology may be regulated through separate pathways. 
The independent and possibly alternative pathways for 
the regulation of these two cellular events have been 
suggested by others [ 16,171. 
For certain cell lines, MSH binding is strongly depen- 
dent on cell cycle and cell density [ 181. Our binding ex- 
periments were performed on confluent monolayer 
cultures, and the effects of RA on the cell cycle as they 
relate to MSH binding remain to be studied more exten- 
sively. 
RA alone has been shown to inhibit,proliferation and 
clonogenicity of numerous melanoma cell lines in vitro, 
and has been used parenterally and topically [ 191 to in- 
hibit melanoma growth in experimental animals. On the 
other hand, the MSH receptor has been suggested as a 
target for antimelanoma chemotherapy via the use of 
hormone toxin/conjugates (e.g. daunomycin) [20,22] 
or by the use of hormone/antibody conjugates to 
enhance cytotoxic lymphocyte killing of melanoma cells 
[22]. The current study raises the intriguing possibility 
of combining both RA and MSH-toxin or antibody 
conjugates in one treatment regimen. It may be possible 
that RA would not only inhibit tumor growth but might 
greatly enhance the effects of the hormone conjugates 
by up-regulating cellular receptors for the hormone. 
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